These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17596671)

  • 1. A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.
    Lee SY; Nam MH; Kim JS; Kim JW
    J Korean Med Sci; 2007 Jun; 22(3):557-9. PubMed ID: 17596671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9.
    Lee SY; Kim JS; Kim JW
    Yonsei Med J; 2005 Dec; 46(6):843-6. PubMed ID: 16385662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
    Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
    Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
    Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
    Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.
    Wilke RA; Berg RL; Vidaillet HJ; Caldwell MD; Burmester JK; Hillman MA
    Clin Med Res; 2005 Nov; 3(4):207-13. PubMed ID: 16303885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
    Gage BF; Eby C; Milligan PE; Banet GA; Duncan JR; McLeod HL
    Thromb Haemost; 2004 Jan; 91(1):87-94. PubMed ID: 14691573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
    N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
    Avery PJ; Jorgensen A; Hamberg AK; Wadelius M; Pirmohamed M; Kamali F;
    Clin Pharmacol Ther; 2011 Nov; 90(5):701-6. PubMed ID: 22012312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
    Voora D; Eby C; Linder MW; Milligan PE; Bukaveckas BL; McLeod HL; Maloney W; Clohisy J; Burnett RS; Grosso L; Gatchel SK; Gage BF
    Thromb Haemost; 2005 Apr; 93(4):700-5. PubMed ID: 15841315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
    Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
    Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.
    Lima MV; Ribeiro GS; Mesquita ET; Victer PR; Vianna-Jorge R
    Eur J Clin Pharmacol; 2008 Jan; 64(1):9-15. PubMed ID: 17955230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
    van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
    Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
    Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
    Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
    Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
    Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.
    Mlynarsky L; Bejarano-Achache I; Muszkat M; Caraco Y
    Eur J Clin Pharmacol; 2012 May; 68(5):617-27. PubMed ID: 22071881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.